Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Liabilities and Shareholders Equity (2020 - 2025)

SAB Biotherapeutics' Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $172.8 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 291.01% year-over-year to $172.8 million; the TTM value through Dec 2025 reached $424.5 million, up 83.57%, while the annual FY2025 figure was $172.8 million, 291.01% up from the prior year.
  • Liabilities and Shareholders Equity reached $172.8 million in Q4 2025 per SABSW's latest filing, down from $183.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $183.4 million in Q3 2025 to a low of $28.3 million in Q3 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $75.5 million, with a median of $60.7 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: plummeted 55.09% in 2022, then soared 291.01% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $81.1 million in 2021, then tumbled by 37.26% to $50.9 million in 2022, then skyrocketed by 64.9% to $83.9 million in 2023, then tumbled by 47.35% to $44.2 million in 2024, then skyrocketed by 291.01% to $172.8 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Liabilities and Shareholders Equity are $172.8 million (Q4 2025), $183.4 million (Q3 2025), and $30.1 million (Q2 2025).